The current study demonstrated the potential utility of combining a proteomic antibody microarray and quantitative ligand-binding assays to screen for and validate differentially expressed proteins in patients with neurodegenerative disorders, including elevated CD14 in CSF from patients with Alzheimer’s disease and osteopontin in CSF from patients with Parkinson’s disease. The gene discussed is CD14; the disease is early-onset autosomal dominant Alzheimer disease.